Determinants of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: The EPICAL study

American Heart Journal

Volumn 139, Issue 4, 2000, Pages 624-631

  Echemann, M ^a,b   Zannad, Faiez ^b,c,d   Briancon S ^a   Juilliere Y ^c   Mertes P M ^c   Virion, J M ^a,b   Villemot, J P ^c  

^a European Neuromuscular Center ENMC   (France)

^b INSERM   (France)

^c Services de Cardiologie et de Chirurgie Cardiaque   (France)

^d UNIVERSITÉ DE LORRAINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CILAZAPRIL; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; FUROSEMIDE; LISINOPRIL; NITRATE; ORAL ANTIDIABETIC AGENT; PERINDOPRIL; QUINAPRIL; RAMIPRIL; SPIRONOLACTONE; TRANDOLAPRIL; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME INHIBITION; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL RATE; SYSTOLE; TREATMENT OUTCOME;

EID: 0034074381     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(00)90039-5     Document Type: Article

References (43)

1. 1. Gavras H. The place of angiotensin-converting inhibition in the treatment of cardiovascular disease. N Engl J Med 1988;319:1541-3.
2. 2. Forker AD. A cardioiogist’s perspective on evolving concepts in the management of congestive heart failure. J Clin Pharmacol 1996; 36:973-84.
3. 3. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival study (CONSENSUS). N Engl J Med 1987;316:1429-35.
4. 4. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection and congestive heart failure. N Engl J Med 1991;325:293-302.
5. 5. Kleber FX, NiemÖlle L, Doering W. Impact of converting enzyme inhibition on progression of chronic heart failure: results of the Munich Mild Heart Failure Trial (MHFT). Br Heart J 1992;67:289-96.
6. 6. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-6.
7. 7. Pfeffer MA, Braunwald E, Moye LA, SAVE Investigators. Effects of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-77.
8. 8. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effects of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342:821-8.
9. 9. Ambrosini E, Borghi C, Magnani B. The effects of angiotensin-converting-enzyme inhibitor zofenopril on mortality after anterior myocardial infarction. N Engl J Med 1995;332:80-5.
10. 10. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico, Gissi-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular dysfunction after acute myocardial infarction. Lancet 1994;343:1115-22.
11. 11. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-6.
12. 12. Binetti G, Senni M, Colombo F, et al. Medical treatment of end-stage heart failure. Cardiovasc Drugs Ther 1996;10:617-22.
13. 13. Packer M. Treatment of chronic heart failure. Lancet 1992;340:92-5.
14. 14. Cohn J. The management of heart failure. N Engl J Med 1996; 335:490-8.
15. 15. Task Force of the Working Group on Heart Failure of the European Society of Cardiology. The treatment of heart failure. Eur Heart J 1997;8:736-53.
16. 16. Kleber FX, Wensel R. Current guidelines for the treatment of congestive heart failure. Drugs 1996;51:89-98.
17. 17. ACC/AHA Task force Report. Guidelines for the evaluation and management of heart failure. J Am Coll Cardiol 1995;26:1376-98.
18. 18. Packer M. Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice? J Am Coll Cardiol 1996;28:1323-7.
19. 19. Visser F, Visser C. Current controversies with ACE inhibitor treatment in heart failure. Cardiology 1996;87:23-8.
20. 20. Zannad F, Briançon S, Juillière Y, et al. Incidence, clinical and etiologic features and outcomes of advanced chronic heart failure: the EPICAL study. J Am Coll Cardiol 1999;33:734-42.
21. 21. Dixon WJ. BMDP Statistical Software Manual. Berkeley, Calif: University of California Press; 1992.
22. 22. Stevenson WG, Stevenson LW, Middlekauff HR, et al. Improving survival for patients with advanced heart failure: a study of 737 consecutive patients. J Am Coll Cardiol 1995;26:1417-23.
23. 23. Califf RM, Adams KF, McKenna W, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997;134:44-54.
24. 24. Bourassa MG, Gurné O, Bangdiwala SI, et al. Natural history and patterns of current practice in heart failure. J Am Coll Cardiol 1993; 22:14A19A.
25. 25. Philbin EF, Andreaou C, Rocco TA, et al. Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. Am J Cardiol 1996;77:832-8.
26. 26. Philbin EF, Rocco TA. Use of angiotensin-converting enzyme inhibitors in heart failure with preserved left ventricular systolic function. Am Heart J 1997;134:188-95.
27. 27. Senni M, Tribouilloy C, Rodeheffer R, et al. Congestive heart failure in the community: a study of all cases in Olmsted County, Minnesota, in 1991. Circulation 1998;98:2282-9.
28. 28. SEOSI Investigators. Survey on heart failure in Italian hospital cardiology units: results of the SEOSI study. Eur Heart J 1997; 18:1457-64.
29. 29. McDermott MMG, Feinglass J, Lee P, et al. Heart failure between 1986 and 1994: temporal trends in drug-prescribing practices, hospital readmissions, and survival at an academic medical center. Am Heart J 1997;134:901-9.
30. 30. Philbin E, Cotto M, Rocco T, et al. Association between diuretic use, clinical response, and death in acute heart failure. Am J Cardiol 1997;80:519-22.
31. 31. Teo K, Montague T, Ackman M, and Clinical Quality Improvement Network Investigators. Mortality risk and patterns of practice in 4606 acute care patients with congestive heart failure: the relative importance of age, sex, and medical therapy. Arch Intern Med 1996;156: 1669-73.
32. 32. Philbin EF, Santella RN, Rocco TA Jr. Angiotensin-converting enzyme inhibitor use in older patients with heart failure and renal dysfunction. J Am Geriatr Soc 1999;47:302-8.
33. 33. Houghton A, Cowley A. Why are angiotensin converting enzyme inhibitors underutilized in the treatment of heart failure by general practitioners? Int J Cardiol 1997;59:7-10.
34. 34. Reis SE, Holubkov R, Edmundowicz D, et al. Treatment of patients admitted to the hospital with congestive heart failure: specialty-related disparities in practice patterns and outcomes. J Am Coll Cardiol 1997;30:733-8.
35. 35. Edep ME, Shah NB, Tateo IM, et al. Differences between primary care physicians and cardiologists in management of congestive heart failure: relation to practice guidelines. J Am Coll Cardiol 1997;30:518-26.
36. 36. Pitt B. ACE inhibitor co-therapy in patients with heart failure: rationale for the randomized aldactone evaluation study (RALES). Eur Heart J 1995;16[suppl N]:107-10.
37. 37. Zannad F. Angiotensin-converting enzyme inhibitor and spironolactone combination therapy: new objectives in congestive heart failure treatment. Am J Cardiol 1993;71:34A-39A.
38. 38. Navhety A, Donker J, Nauta J, et al. Spironolactone in congestive heart failure refractory high dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol 1993;71:A21-A28.
39. 39. RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic heart failure (The Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996;78:902-7.
40. 40. Pitt B, Zannad F, Remme W, et al, for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
41. 41. Narang G, Swedberg K, Cleland G. What is the ideal study design for evaluation of treatment of heart failure? Insights from trials assessing the effect of ACE inhibitors on exercise capacity. Eur Heart J 1996;17:120-34.
42. 42. NETWORK Investigators. Clinical outcome with enalapril in symptomatic chronic heart failure: a dose comparison. Eur Heart J 1998; 19:481-9.
43. 43. Packer M, Poole-Wilson P, Armstrong P, et al. Comparative effects of low-dose versus high-dose lisinopril on survival and major events in chronic heart failure: the Assessment of Treatment with lisinopril And Survival study (ATLAS) [abstract]. Eur Heart J 1998;19:905-142.